Catalog No.
YHB61301
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Glu421-Ala663
Predicted molecular weight
29.15 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
O95342
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
BSEP, Bile salt export pump, ABCB11, ATP-binding cassette sub-family B member 11
Correction of a Traffic-Defective Missense ABCB11 Variant Responsible for Progressive Familial Intrahepatic Cholestasis Type 2., PMID:40508041
Immunohistochemistry in Progressive Familial Intrahepatic Cholestasis (PFIC): Bridging Gap Between Morphology and Genetics., PMID:40384941
Biomarker-driven drug repurposing for NAFLD-associated hepatocellular carcinoma using machine learning integrated ensemble feature selection., PMID:40313868
Cholestasis in hepatitis E virus infection., PMID:40308815
Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation., PMID:40234449
A structural and mechanistic model for BSEP dysfunction in PFIC2 cholestatic disease., PMID:40195555
Model of baseline clinicopathological features predicts non-resolution of drug-induced liver injury at 6 months., PMID:40180706
β-Sitosterol protects against lithocholic acid-induced hepatotoxicity and cholestasis via farnesoid X receptor-mediated regulation of transporters and enzymes in vitro and in vivo., PMID:40120651
Inhibition of ABC transporters by sorafenib and lenvatinib: implications for drug-induced cholestasis., PMID:40096842
Suppression of FOXO1 activity by SIRT1-mediated deacetylation weakening the intratumoral androgen autocrine function in glioblastoma., PMID:40075208
Liver fibrosis negatively impacts in vivo gene transfer to murine hepatocytes., PMID:40064848
Efficacy and mechanism of inhibition of the GPR30-PI3K pathway by 4-phenylbutyric acid in the treatment of intrahepatic cholestasis of pregnancy., PMID:40063113
Potential of connexin 32 as a predictive marker for drug-induced cholestatic liver injury in a collagen vitrigel-culture model of HepG2-NIAS cells, a new subline of HepG2 cells, with bile canaliculus-like structures., PMID:40024757
In Vitro-In Silico Models to Elucidate Mechanisms of Bile Acid Disposition and Cellular Aerobics in Human Hepatocytes., PMID:40016501
Repression of bile salt efflux pump expression by tri-ortho-cresyl phosphate in cultured human hepatic cells., PMID:39929294
A family with gallstone disease: defining inherited risk in the era of clinical genetic testing., PMID:39786488
NXT629 Ameliorates Cholesterol Gallstones in Mice Model by Improving Lipid Metabolism Disorder and Cholesterol Homeostasis Through Inhibiting the GPAM Pathway., PMID:39724467
Loss of hepatocyte Usp53 protects mice from a form of xenobiotic-induced liver injury., PMID:39705897
Interleukin 1 β suppresses bile acid-induced BSEP expression via a CXCR2-dependent feedback mechanism., PMID:39680527
A Case of Progressive Familial Intrahepatic Cholestasis Type-3., PMID:39618628
Mitigation of polystyrene microplastic-induced hepatotoxicity in human hepatobiliary organoids through bile extraction., PMID:39571255
Desmodium styracifolium (Osb.) Merr. Extracts alleviate cholestatic liver disease by FXR pathway., PMID:39454708
A Novel Variant (p.Leu1054Arg) in ABCB11 Presenting with Progressive Familial Intrahepatic Cholestasis (PFIC) with Congenital Hypothyroidism., PMID:39271630
The spectrum of novel ABCB11 gene variations in children with progressive familial intrahepatic cholestasis type 2 in Pakistani cohorts., PMID:39143102
ABC transporters involved in respiratory and cholestatic diseases: From rare to very rare monogenic diseases., PMID:39111603
Farnesoid X Receptor: Effective alleviation of rifampicin -induced liver injury., PMID:39068755
Cholesterol Allosterically Modulates the Structure and Dynamics of the Taurocholate Export Pump (ABCB11)., PMID:39058973
Oleanolic acid induces hepatic injury by disrupting hepatocyte tight junction and dysregulation of farnesoid X receptor-mediated bile acid efflux transporters., PMID:39030772
Pulsatilla decoction alleviates DSS-induced UC by activating FXR-ASBT pathways to ameliorate disordered bile acids homeostasis., PMID:38974033
What's new in pediatric genetic cholestatic liver disease: advances in etiology, diagnostics and therapeutic approaches., PMID:38957097
Tauroursodeoxycholate prevents estradiol 17β-d-glucuronide-induced cholestasis and endocytosis of canalicular transporters by switching off pro-cholestatic signaling pathways., PMID:38876186
Fine particulate matter disrupts bile acid homeostasis in hepatocytes via binding to and activating farnesoid X receptor., PMID:38821196
Puerarin Modulates Hepatic Farnesoid X Receptor and Gut Microbiota in High-Fat Diet-Induced Obese Mice., PMID:38791314
From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling., PMID:38755481
Dual Deletion of Keap1 and Rbpjκ Genes in Liver Leads to Hepatomegaly and Hypercholesterolemia., PMID:38731931
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial., PMID:38723644
Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway., PMID:38663779
A Rare Case of Benign Recurrent Intrahepatic Cholestasis Initially Diagnosed in Middle-age., PMID:38607191
An Effort to Identify Genetic Determinants in Siblings With Wilson Disease Manifesting Striking Clinical Heterogeneity: An Exome Profiling Study of Two Indian Families., PMID:38552405
CYP7A1 Gene Induction via SHP-Dependent or Independent Mechanisms can Increase the Risk of Drug-Induced Liver Injury Independently or in Synergy with BSEP Inhibition., PMID:38485279
Genetics of Gallstone Disease and Their Clinical Significance: A Narrative Review., PMID:38426197
The noncanonical nucleotide binding site 1 of the bile salt export pump is optimized for proper function of the transporter., PMID:38328902
Cav-1 regulates the bile salt export pump on the canalicular membrane of hepatocytes by PKCα-associated signalling under cholesterol stimulation., PMID:38164042
Sphincter of Oddi Dysfunction Induces Gallstone by Inhibiting the Expression of ABCB11 via PKC-α., PMID:38158489
Molecular and computational characterization of ABCB11 and ABCG5 variants in Tunisian patients with neonatal/infantile low-GGT intrahepatic cholestasis: Genetic diagnosis and genotype-phenotype correlation assessment., PMID:38108658
Structural basis of bile salt extrusion and small-molecule inhibition in human BSEP., PMID:37949847
Ursolic acid attenuates cholestasis through NRF2-mediated regulation of UGT2B7 and BSEP/MRP2., PMID:37812240
The Mutational Landscape Of Genetic Cholestatic Diseases In Pakistani Children., PMID:37697751
Bsep/Abcb11 knockout ameliorates Schistosoma mansoni liver pathology by reducing parasite fecundity., PMID:37641872
An Enhancer Within Abcb11 Regulates G6pc2 in C57BL/6 Mouse Pancreatic Islets., PMID:37552875
For research use only. Not for human or drug use.
